Ubiquitous Yet Distinct Expression of Podocalyxin on Vascular Surfaces in Normal and Tumor Tissues in the Rat

Overview

Journal J Vasc Res

Specialty Cardiology & Vascular Diseases

Date 2009 Jan 15

PMID 19142011

Citations 7

Authors

Jacqueline E Testa

Adrian Chrastina

Yan Li

Phil Oh

Jan E Schnitzer

Affiliations

Soon will be listed here.

Abstract

Background/aims: The vasculature has become an important target in the development of therapies for increasing numbers of human diseases, yet there are few reliable markers available to identify the endothelium in rodent models. We have characterized the expression, subcellular localization and accessibility of the rat pan-endothelial marker podocalyxin (podxl) using a newly developed monoclonal antibody (mAb), G278.

Methods: podxl expression and accessibility to binding by G278 were determined in the rat by a variety of experimental approaches.

Results: mAb G278 reliably immunostained blood vessels of all types and of every size in fresh-frozen, fixed-frozen and paraffin-embedded sections of all tissues, but did not stain lymphatic vessels. Western blotting, in vivo imaging and biodistribution analyses demonstrated that the highest levels of endothelial podxl were found in the lung and heart. We also determined that podxl is not enriched in caveolae and that its expression can be modulated in the tumor microenvironment.

Conclusion: Our study shows that podxl is a better identifier of rat endothelia than are some of the more commonly used markers and that mAb G278 is a robust antibody for use not only in identifying rat blood vessels but also as a tool to elucidate podxl function.

Citing Articles

Anatomy and function of the vertebral column lymphatic network in mice.

Jacob L, Boisserand L, Geraldo L, de Brito Neto J, Mathivet T, Antila S Nat Commun. 2019; 10(1):4594.

PMID: 31597914 PMC: 6785564. DOI: 10.1038/s41467-019-12568-w.

In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors.

Oh P, Testa J, Borgstrom P, Witkiewicz H, Li Y, Schnitzer J Nat Med. 2014; 20(9):1062-8.

PMID: 25129480 DOI: 10.1038/nm.3623.

Overcoming key technological challenges in using mass spectrometry for mapping cell surfaces in tissues.

Griffin N, Schnitzer J Mol Cell Proteomics. 2010; 10(2):R110.000935.

PMID: 20548103 PMC: 3033688. DOI: 10.1074/mcp.R110.000935.

Lung vascular targeting using antibody to aminopeptidase P: CT-SPECT imaging, biodistribution and pharmacokinetic analysis.

Chrastina A, Valadon P, Massey K, Schnitzer J J Vasc Res. 2010; 47(6):531-43.

PMID: 20431301 PMC: 2945271. DOI: 10.1159/000313880.

Identification and expression profiling of blood-brain barrier membrane proteins.

Agarwal N, Lippmann E, Shusta E J Neurochem. 2009; 112(3):625-35.

PMID: 19895664 PMC: 2809131. DOI: 10.1111/j.1471-4159.2009.06481.x.

References

Sassetti C, Tangemann K, Singer M, Kershaw D, Rosen S . Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34. J Exp Med. 1998; 187(12):1965-75. PMC: 2212365. DOI: 10.1084/jem.187.12.1965. View

Miettinen A, Solin M, Reivinen J, Juvonen E, Vaisanen R, Holthofer H . Podocalyxin in rat platelets and megakaryocytes. Am J Pathol. 1999; 154(3):813-22. PMC: 1866405. DOI: 10.1016/S0002-9440(10)65328-X. View

Sizemore S, Cicek M, Sizemore N, Ng K, Casey G . Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res. 2007; 67(13):6183-91. DOI: 10.1158/0008-5472.CAN-06-3575. View

McNagny K, Pettersson I, Rossi F, Flamme I, Shevchenko A, Mann M . Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J Cell Biol. 1997; 138(6):1395-407. PMC: 2132552. DOI: 10.1083/jcb.138.6.1395. View

Rizzo V, Morton C, Depaola N, Schnitzer J, Davies P . Recruitment of endothelial caveolae into mechanotransduction pathways by flow conditioning in vitro. Am J Physiol Heart Circ Physiol. 2003; 285(4):H1720-9. DOI: 10.1152/ajpheart.00344.2002. View

Doyonnas R, Kershaw D, Duhme C, Merkens H, Chelliah S, Graf T . Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med. 2001; 194(1):13-27. PMC: 2193439. DOI: 10.1084/jem.194.1.13. View

Heukamp L, Fischer H, Schirmacher P, Chen X, Breuhahn K, Nicolay C . Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology. 2006; 49(3):242-7. DOI: 10.1111/j.1365-2559.2006.02489.x. View

Carmeliet P . Angiogenesis in life, disease and medicine. Nature. 2005; 438(7070):932-6. DOI: 10.1038/nature04478. View

Schnitzer J, Oh P, McIntosh D . Role of GTP hydrolysis in fission of caveolae directly from plasma membranes. Science. 1996; 274(5285):239-42. DOI: 10.1126/science.274.5285.239. View

10.

Casey G, Neville P, Liu X, Plummer S, Cicek M, Krumroy L . Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet. 2006; 15(5):735-41. DOI: 10.1093/hmg/ddi487. View

11.

Larrucea S, Butta N, Rodriguez R, Alonso-Martin S, Arias-Salgado E, Ayuso M . Podocalyxin enhances the adherence of cells to platelets. Cell Mol Life Sci. 2007; 64(22):2965-74. PMC: 11136142. DOI: 10.1007/s00018-007-7374-6. View

12.

Valadon P, Garnett J, Testa J, Bauerle M, Oh P, Schnitzer J . Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci U S A. 2005; 103(2):407-12. PMC: 1326159. DOI: 10.1073/pnas.0506938103. View

13.

Russell J, ODonoghue J, Finn R, Koziorowski J, Ruan S, Humm J . Iodination of annexin V for imaging apoptosis. J Nucl Med. 2002; 43(5):671-7. View

14.

McIntosh D, Tan X, Oh P, Schnitzer J . Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A. 2002; 99(4):1996-2001. PMC: 122308. DOI: 10.1073/pnas.251662398. View

15.

Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D . Endothelial cell membranes contain podocalyxin--the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol. 1986; 102(2):484-91. PMC: 2114082. DOI: 10.1083/jcb.102.2.484. View

16.

Lin W, Pang V, Liu C, Chen J, Shen K, Lin Y . Pleomorphic extra-renal manifestation of the glomerular podocyte marker podocalyxin in tissues of normal beagle dogs. Histochem Cell Biol. 2006; 127(4):399-414. DOI: 10.1007/s00418-006-0252-8. View

17.

Doyonnas R, Nielsen J, Chelliah S, Drew E, Hara T, Miyajima A . Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood. 2005; 105(11):4170-8. DOI: 10.1182/blood-2004-10-4077. View

18.

St Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E . Genes expressed in human tumor endothelium. Science. 2000; 289(5482):1197-202. DOI: 10.1126/science.289.5482.1197. View

19.

Takeda T, Go W, ORLANDO R, Farquhar M . Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol Biol Cell. 2000; 11(9):3219-32. PMC: 14987. DOI: 10.1091/mbc.11.9.3219. View

20.

Dekan G, Miettinen A, Schnabel E, Farquhar M . Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy. Am J Pathol. 1990; 137(4):913-27. PMC: 1877537. View